![]() With similar or better efficacy and safety outcomes and easier use in the outpatient setting compared with the standard-of-care vitamin K antagonists and low molecular weight heparin, DOACs are now endorsed as first-line treatment of indications including prevention of stroke and systemic embolism in nonvalvular atrial fibrillation and treatment of venous thromboembolism. Tell your doctor if have hereditary fructose intolerance.ĭo not take idarucizumab if you are allergic to idarucizumab or to any of its ingredients.Direct oral anticoagulants (DOACs) have significantly improved the care of patients requiring anticoagulation. Patients with hereditary fructose intolerance may be at risk of adverse reactions such as low blood sugar, low phosphate, metabolic acidosis, increase in uric acid, and acute liver failure. Hereditary Fructose Intolerance to Sorbitol Excipient. Idarucizumab contains sorbitol.These may include fever, difficulty breathing due to tightening of the airways, hyperventilation, rash, and itching, Your doctor will discontinue idarucizumab if this occurs. Hypersensitivity reactions (serious allergic reaction).Some patients may require an additional dose of idarucizumab. Recurrence of bleeding and increase in coagulation parameters. ![]() Your doctor will resume Pradaxa as soon as medically appropriate. Pradaxa treatment can be initiated 24 hours after administration of idarucizumab. Blood clots. Idarucizumab reverses Pradaxa so patients are at exposed to the thrombotic risk (blood clots) of the underlying disease that Pradaxa is being given for.Serious side effects have been reported with idarucizumab including the following: ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |